This is a preview of subscription content, log in via an institution to check access.
Literatur
Russ GR,Tedesco-Silva H, Kuypers DR et al (2013) Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. Am J Transplant 13(7):1746–1756
Spitaler M, Cantrell DA (2004) Protein kinase C and beyond. Nat Immunol 5(8):785–790
Mecklenbräuker I, Saijo K, Zheng NY et al (2002) Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature 416(6883):860–865
Budde K, Sommerer C, Becker T et al (2010) Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 10(3):571–581
Friman S, Arns W, Nashan B et al (2011) Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 11(7):1444–1455
o A (2013)Transplantation: development of sotrastaurin halted in kidney transplantation. Nat Rev Nephrol 9(7):370
Tedesco-Silva H, Kho MM, Hartmann A et al (2013) Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients. Am J Transplant 13(7):1757–1768
Einhaltung ethischer Richtlinien
Interessenkonflikt
L.J. Lehner gibt an, dass kein Interessenkonflikt besteht. K. Budde hat finanzielle Unterstützung für Forschungsprojekte, Reisen, Vorträge und Beratertätigkeit von folgenden Firmen erhalten: AiCuris, Astellas, Bristol-Myers Squibb, Hexal, LifeCycle Pharma, Novartis Pharma, Roche AG, Siemens AG, TCL Pharma und Pfizer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehner, L., Budde, K. Sotrastaurin. Nephrologe 8, 428–430 (2013). https://doi.org/10.1007/s11560-013-0782-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-013-0782-8